Workflow
精细化工
icon
Search documents
*ST亚太重整:每10股转增5股 北京星箭牵头注资4.04亿
Core Viewpoint - *ST Asia Pacific (000691.SZ) has disclosed a restructuring plan aimed at resolving over 338 million yuan in debt through a combination of capital reserve conversion to share capital and the introduction of restructuring investors [1] Group 1: Restructuring Plan - The company plans to convert its existing total share capital of 323 million shares at a ratio of 5 shares for every 10 shares, resulting in an increase of 162 million shares [1] - The newly issued shares will not be allocated to existing shareholders but will be fully subscribed by restructuring investors [1] - Beijing Xingjian, the industrial investor, will acquire 75 million shares at 2.4 yuan per share, while strategic investor Lanzhou Financial Holdings will acquire 23.2754 million shares at the same price [1] Group 2: Financial Contributions - The restructuring investors will inject a total of 404 million yuan to support the company's business transformation [1] - A deposit of 73 million yuan has been donated by the restructuring investors to alleviate the company's liquidity pressure [1] - The debt repayment plan indicates that secured creditors will receive full cash repayment within the assessed value of the collateral, while ordinary creditors will have a tiered repayment scheme [1] Group 3: Business Transformation - Post-restructuring, the company aims to leverage the technological advantages of the industrial investor in the military guidance field to gradually introduce smart devices and navigation systems [1] - The company plans to optimize the product structure of its subsidiary, Lingang Yanuo, and extend into the new energy sector, specifically lithium battery electrolyte additives [1] - The company anticipates that its net assets will turn positive after the restructuring is completed [1]
*ST亚太:控股股东无条件豁免公司债务7500万元
Group 1 - The core point of the article is that *ST Asia Pacific (000691) announced a debt waiver of 75 million yuan by its controlling shareholder, Guangzhou Wanshun Technology Co., Ltd., to support the company's development and alleviate debt pressure [2] - The debt waiver is unconditional and irrevocable, which will increase the company's capital reserve by 75 million yuan [2] - The purpose of the debt waiver is to effectively address the company's debt issues and enhance its ability to continue operations [2] Group 2 - As of the report date, Guangzhou Wanshun holds a total of 16.40% of the voting shares in the company [2] - *ST Asia Pacific primarily engages in the research, production, and sales of pesticide intermediates and pharmaceutical intermediates within the fine chemical products sector [2] - For the first three quarters, the company achieved total operating revenue of 353 million yuan, representing a year-on-year increase of 1.20% [2]
天赐材料:12月9日召开董事会会议
Mei Ri Jing Ji Xin Wen· 2025-12-09 12:32
截至发稿,天赐材料市值为812亿元。 每经头条(nbdtoutiao)——处方药变"瘾品":国内首次报告普瑞巴林滥用致成瘾病例,网络平台暴 露"无病历可购药"漏洞,列管与否尚需科学考量 (记者 王瀚黎) 每经AI快讯,天赐材料(SZ 002709,收盘价:39.96元)12月9日晚间发布公告称,公司第六届第三十 九次董事会会议于2025年12月9日在广州市黄埔区云埔工业区东诚片康达路公司办公楼二楼培训厅通过 现场的方式召开。会议审议了《关于部分募投项目延期的议案》等文件。 2025年1至6月份,天赐材料的营业收入构成为:精细化工行业占比100.0%。 ...
博苑股份(301617) - 2025年12月9日投资者关系活动记录表
2025-12-09 10:22
Group 1: Company Overview - The company, Shandong Boyuan Pharmaceutical Chemical Co., Ltd., focuses on fine chemicals, with iodides being the primary revenue contributor [2]. - The current production capacity for iodide products is 4,100 tons/year, with an additional 4,000 tons/year in trial production [2]. Group 2: Product Details - The main categories of fine chemicals include iodides, luminescent materials, hexamethyldisilazane, and precious metal catalysts, with iodides leading in revenue [2]. - The inorganic iodides include potassium iodide, potassium iodate, sodium iodide, hydriodic acid, and cuprous iodide, while organic iodides consist of trimethyl iodide and iodomethane [2]. Group 3: Market Outlook - The market for inorganic iodides is expected to grow due to increasing demand in the pharmaceutical sector, driven by rising healthcare spending and aging populations [3]. - The demand for iodinated contrast agents in medical imaging (CT and MRI) is projected to rise, contributing to the expansion of the domestic contrast agent market [3]. - In the electronics manufacturing sector, the shift of global panel production to China is increasing the domestic market share of polarizer manufacturers, with iodinated polarizers holding an 80%-90% market share [3]. Group 4: Shareholder Information - A total of 19,630,000 shares will be released from lock-up on December 11, 2025, with no current plans for shareholder reduction reported [3]. - The company will disclose any future reduction plans in accordance with legal requirements [3]. Group 5: Raw Material Sourcing - The company sources iodine through a dual-channel model of "resource recycling and recovery + import supplementation" [5].
华锦股份:12月9日召开董事会会议
Mei Ri Jing Ji Xin Wen· 2025-12-09 08:36
每经AI快讯,华锦股份(SZ 000059,收盘价:5.08元)12月9日晚间发布公告称,公司第八届第十二次 董事会会议于2025年12月9日在公司会议室召开。会议审议了《关于拟聘任会计师事务所的议案》等文 件。 每经头条(nbdtoutiao)——处方药变"瘾品":国内首次报告普瑞巴林滥用致成瘾病例,网络平台暴 露"无病历可购药"漏洞,列管与否尚需科学考量 (记者 王瀚黎) 截至发稿,华锦股份市值为81亿元。 2025年1至6月份,华锦股份的营业收入构成为:石化占比86.47%,精细化工占比8.22%,化学肥料制造 业占比4.47%,其他行业占比0.84%。 ...
奥克股份:公司紧紧围绕环氧衍生绿色低碳精细化工新材料产业链,积极推进技术创新和产品转型升级
Zheng Quan Ri Bao· 2025-12-08 12:41
(文章来源:证券日报) 证券日报网讯 12月8日,奥克股份在互动平台回答投资者提问时表示,公司紧紧围绕环氧衍生绿色低碳 精细化工新材料产业链,积极推进技术创新和产品转型升级,在聚乙二醇医药辅料及原料药、高性能聚 羧酸减水剂聚醚单体等环氧乙烷衍生新材料产品领域,公司相关产品指标均达到全球领先水平。公司始 终秉持务实经营的理念,注重以实际业绩和技术实力赢得市场认可,相关信息已通过定期报告等法定信 息披露渠道向投资者充分披露。未来,公司将继续聚焦主业,加大研发,积极把握国内国际市场机遇。 ...
辽宁盘锦辽滨经开区完善创新培育链
Zhong Guo Jing Ji Wang· 2025-12-08 08:32
近日,在辽宁盘锦市辽滨经开区,投资837亿元的华锦阿美精细化工及原料工程项目正在加紧建设,年 底将全力冲刺机械竣工目标。 2005年成立以来,辽滨经开区地区生产总值增长25倍,工业总产值破千亿,跻身赛迪顾问与石化联合会 化工园区排行榜前20强,分列东北第一、二位,成为盘锦经济核心引擎。2018至2024年实际利用外资 26.9亿美元、进出口总额1187.5亿元。 辽滨经开区管委会副主任吴庆明介绍,辽滨经开区注重创新驱动,放大科技优势。大连理工大学盘锦校 区、大连理工大学盘锦产研院等科研力量集聚,构建了"基础研发—中试熟化—产业放大"体系;完 善"科技型中小企业—高新技术企业—雏鹰瞪羚企业"培育链,省级中试基地架起"实验室—孵化器—开 发区"的转化桥梁,促进了创新要素加速流动。 产业上,辽滨经开区"一核引领、两翼支撑、新兴赋能"生态成型,千万吨炼化、百万吨乙烯筑牢根基, 粮油加工、装备制造、新材料等产业协同发展。政策层面,叠加国家、省、市三级优惠,推出定制化举 措与优厚人才政策,用诚意引才留商。配套方面,基础保障全覆盖,拥有29座万吨级泊位。特别是国家 级循环化改造示范试点顺利通过国家级验收,成功入选2024年 ...
圣奥化学再次入选精细化工双榜单
Zhong Guo Hua Gong Bao· 2025-12-08 02:35
Core Viewpoint - The recent 25th Fine Chemical Industry (Ningdong) Conference highlighted the achievements of Shengao Chemical, which ranked 29th in the "Top 100 Fine Chemicals in China 2025" and 6th in the "Top 10 Innovative Development Enterprises in Fine Chemicals 2025," showing significant improvement from 2024 [1] Group 1: Company Performance - Shengao Chemical has established a strong presence in the polymer additives sector, with a strategic layout across five global production bases, covering over 50 countries and regions [1] - In 2024, the company invested 193 million yuan in R&D, focusing on the development of green and environmentally friendly anti-aging agents, refining plastic additive products, and expanding the flame retardant product chain [1] - The company has achieved breakthroughs in several key technology areas and has received multiple national-level honors [1] Group 2: Sustainability Efforts - Shengao Chemical is making strides towards green sustainability, with a 27.03% reduction in comprehensive energy consumption per ten thousand yuan of output compared to 2020 [1] - The company has also reduced carbon dioxide emissions per ten thousand yuan of output by 20.8% compared to 2020 [1] - A total of 16 carbon reduction projects have been implemented, achieving a carbon reduction of over 20,000 tons of CO2 equivalent through process improvements and enhanced energy utilization [1]
天赐材料:近60个交易日涨幅超65% 控股股东承诺六个月内不减持公司股份
天赐材料主营业务为精细化工新材料的研发、生产和销售,属于精细化工行业,主要产品为锂离子电池 材料、日化材料及特种化学品。2025年前三季度实现营业总收入108.43亿元,同比增长22.34%;归母净 利润4.21亿元,同比增长24.33%。 2025年12月5日,天赐材料收盘价38.59元/股,总市值772亿元。今年以来,累计涨幅超过90%;近60个 交易日,累计涨幅超过65%。 中证智能财讯天赐材料(002709)12月7日晚间公告,公司控股股东徐金富自愿承诺自本公告之日起6个 月内不减持其所持有的公司股票。 资料显示,截至今日,徐金富持有公司股票6.987亿股,占总股本的34.35%,为公司第一大股东。 ...
渤海化学腾笼换鸟拟购泰达新材 标的公司前九月盈利逾3亿增179%
Chang Jiang Shang Bao· 2025-12-07 23:55
Core Viewpoint - Bohai Chemical is actively seeking to resolve its financial difficulties through a significant asset restructuring, which includes selling its core asset Bohai Petrochemical to its controlling shareholder and acquiring control of Anhui Taida New Materials [1][2][6] Group 1: Asset Restructuring - Bohai Chemical plans to sell 100% of Bohai Petrochemical to its controlling shareholder, Tianjin Bohai Chemical Group [2] - The sale of Bohai Petrochemical, which has been a financial burden due to continuous losses, is expected to alleviate the company's performance pressure [6] - Bohai Petrochemical has been a core subsidiary since its acquisition in 2020, but has faced significant losses due to market challenges [1][4] Group 2: Financial Performance - Bohai Chemical's revenue and net profit have significantly declined since 2022, with revenues of 60.48 billion, 32.25 billion, and 47.84 billion from 2022 to 2024, and net losses increasing to -6.32 billion in 2024 [4][5] - In the first three quarters of 2025, the company reported revenues of 28.09 billion, a 16.82% decrease year-on-year, and a net loss of -5.79 billion, a 7.85% decline [4][5] Group 3: Acquisition of Taida New Materials - Bohai Chemical intends to acquire control of Anhui Taida New Materials through a combination of issuing shares and cash payments [8] - Taida New Materials has shown strong profitability, with projected earnings exceeding 300 million in the first three quarters of 2025, representing a 179% year-on-year increase [1][12] - The company specializes in fine chemicals and has a competitive edge in the production of specific chemical products, positioning it as a valuable asset for Bohai Chemical's strategic shift [9][10]